 | • レポートコード：MRC2012B0261 • 出版社/出版日：GlobalInfoResearch / 2020年12月21日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、糖尿病性神経障害治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。糖尿病性神経障害治療薬の種類別市場規模（カプセル、ピル、その他）、用途別市場規模（対称性ニューロパシー、限局性・多巣性ニューロパシー）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：AstraZeneca、MediciNova、Mitsubishi Chemical、Johnson & Johnson、Immune Pharmaceuticals、Takeda、Dong-A Pharmaceutical Co., Ltd.、Avanir Pharmaceuticals、Sangamo BioSciences ・地域別グローバル市場分析 2015年-2020年 ・糖尿病性神経障害治療薬の北米市場（アメリカ、カナダ、メキシコ） ・糖尿病性神経障害治療薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・糖尿病性神経障害治療薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・糖尿病性神経障害治療薬の南米市場（ブラジル、アルゼンチン） ・糖尿病性神経障害治療薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：カプセル、ピル、その他 ・用途別分析：対称性ニューロパシー、限局性・多巣性ニューロパシー ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Diabetic Neurological Disorder Therapeutic Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The global Diabetic Neurological Disorder Therapeutic Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
Market segmentation
Diabetic Neurological Disorder Therapeutic Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Diabetic Neurological Disorder Therapeutic Drug market has been segmented into:
Capsule
Pills
Other
By Application, Diabetic Neurological Disorder Therapeutic Drug has been segmented into:
Symmetrical Neuropathy
Focal and Multifocal Neuropathy
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Diabetic Neurological Disorder Therapeutic Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Diabetic Neurological Disorder Therapeutic Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Diabetic Neurological Disorder Therapeutic Drug market.
The report offers in-depth assessment of the growth and other aspects of the Diabetic Neurological Disorder Therapeutic Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Diabetic Neurological Disorder Therapeutic Drug Market Share Analysis
Diabetic Neurological Disorder Therapeutic Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Diabetic Neurological Disorder Therapeutic Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Diabetic Neurological Disorder Therapeutic Drug sales, revenue and market share for each player covered in this report.
The major players covered in Diabetic Neurological Disorder Therapeutic Drug are:
AstraZeneca
MediciNova
Mitsubishi Chemical
Johnson & Johnson
Immune Pharmaceuticals
Takeda
Dong-A Pharmaceutical Co., Ltd.
Avanir Pharmaceuticals
Sangamo BioSciences
Among other players domestic and global, Diabetic Neurological Disorder Therapeutic Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 Diabetic Neurological Disorder Therapeutic Drug Market Overview
1.1 Product Overview and Scope of Diabetic Neurological Disorder Therapeutic Drug
1.2 Classification of Diabetic Neurological Disorder Therapeutic Drug by Type
1.2.1 Global Diabetic Neurological Disorder Therapeutic Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Type in 2019
1.2.3 Capsule
1.2.4 Pills
1.2.5 Other
1.3 Global Diabetic Neurological Disorder Therapeutic Drug Market by Application
1.3.1 Overview: Global Diabetic Neurological Disorder Therapeutic Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Symmetrical Neuropathy
1.3.3 Focal and Multifocal Neuropathy
1.4 Global Diabetic Neurological Disorder Therapeutic Drug Market by Regions
1.4.1 Global Diabetic Neurological Disorder Therapeutic Drug Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Diabetic Neurological Disorder Therapeutic Drug (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Diabetic Neurological Disorder Therapeutic Drug Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Diabetic Neurological Disorder Therapeutic Drug Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Diabetic Neurological Disorder Therapeutic Drug Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Diabetic Neurological Disorder Therapeutic Drug Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Diabetic Neurological Disorder Therapeutic Drug Status and Prospect (2015-2025)
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca SWOT Analysis
2.1.4 AstraZeneca Product and Services
2.1.5 AstraZeneca Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2019)
2.2 MediciNova
2.2.1 MediciNova Details
2.2.2 MediciNova Major Business
2.2.3 MediciNova SWOT Analysis
2.2.4 MediciNova Product and Services
2.2.5 MediciNova Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2019)
2.3 Mitsubishi Chemical
2.3.1 Mitsubishi Chemical Details
2.3.2 Mitsubishi Chemical Major Business
2.3.3 Mitsubishi Chemical SWOT Analysis
2.3.4 Mitsubishi Chemical Product and Services
2.3.5 Mitsubishi Chemical Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2019)
2.4 Johnson & Johnson
2.4.1 Johnson & Johnson Details
2.4.2 Johnson & Johnson Major Business
2.4.3 Johnson & Johnson SWOT Analysis
2.4.4 Johnson & Johnson Product and Services
2.4.5 Johnson & Johnson Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2019)
2.5 Immune Pharmaceuticals
2.5.1 Immune Pharmaceuticals Details
2.5.2 Immune Pharmaceuticals Major Business
2.5.3 Immune Pharmaceuticals SWOT Analysis
2.5.4 Immune Pharmaceuticals Product and Services
2.5.5 Immune Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2019)
2.6 Takeda
2.6.1 Takeda Details
2.6.2 Takeda Major Business
2.6.3 Takeda Product and Services
2.6.4 Takeda Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2019)
2.7 Dong-A Pharmaceutical Co., Ltd.
2.7.1 Dong-A Pharmaceutical Co., Ltd. Details
2.7.2 Dong-A Pharmaceutical Co., Ltd. Major Business
2.7.3 Dong-A Pharmaceutical Co., Ltd. Product and Services
2.7.4 Dong-A Pharmaceutical Co., Ltd. Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2019)
2.8 Avanir Pharmaceuticals
2.8.1 Avanir Pharmaceuticals Details
2.8.2 Avanir Pharmaceuticals Major Business
2.8.3 Avanir Pharmaceuticals Product and Services
2.8.4 Avanir Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2019)
2.9 Sangamo BioSciences
2.9.1 Sangamo BioSciences Details
2.9.2 Sangamo BioSciences Major Business
2.9.3 Sangamo BioSciences Product and Services
2.9.4 Sangamo BioSciences Diabetic Neurological Disorder Therapeutic Drug Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Diabetic Neurological Disorder Therapeutic Drug Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Diabetic Neurological Disorder Therapeutic Drug Players Market Share
3.2.2 Top 10 Diabetic Neurological Disorder Therapeutic Drug Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Diabetic Neurological Disorder Therapeutic Drug Revenue and Market Share by Regions
4.2 North America Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
4.3 Europe Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
4.5 South America Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
5 North America Diabetic Neurological Disorder Therapeutic Drug Revenue by Countries
5.1 North America Diabetic Neurological Disorder Therapeutic Drug Revenue by Countries (2015-2020)
5.2 USA Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
5.3 Canada Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
5.4 Mexico Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
6 Europe Diabetic Neurological Disorder Therapeutic Drug Revenue by Countries
6.1 Europe Diabetic Neurological Disorder Therapeutic Drug Revenue by Countries (2015-2020)
6.2 Germany Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
6.3 UK Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
6.4 France Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
6.5 Russia Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
6.6 Italy Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Diabetic Neurological Disorder Therapeutic Drug Revenue by Countries
7.1 Asia-Pacific Diabetic Neurological Disorder Therapeutic Drug Revenue by Countries (2015-2020)
7.2 China Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
7.3 Japan Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
7.4 Korea Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
7.5 India Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
8 South America Diabetic Neurological Disorder Therapeutic Drug Revenue by Countries
8.1 South America Diabetic Neurological Disorder Therapeutic Drug Revenue by Countries (2015-2020)
8.2 Brazil Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
8.3 Argentina Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Diabetic Neurological Disorder Therapeutic Drug by Countries
9.1 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Revenue by Countries (2015-2020)
9.2 Saudi Arabia Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
9.3 UAE Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
9.4 Egypt Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
9.5 South Africa Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Diabetic Neurological Disorder Therapeutic Drug Revenue and Market Share by Type (2015-2020)
10.2 Global Diabetic Neurological Disorder Therapeutic Drug Market Forecast by Type (2019-2024)
10.3 Capsule Revenue Growth Rate (2015-2025)
10.4 Pills Revenue Growth Rate (2015-2025)
10.5 Other Revenue Growth Rate (2015-2025)
11 Global Diabetic Neurological Disorder Therapeutic Drug Market Segment by Application
11.1 Global Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Application (2015-2020)
11.2 Diabetic Neurological Disorder Therapeutic Drug Market Forecast by Application (2019-2024)
11.3 Symmetrical Neuropathy Revenue Growth (2015-2020)
11.4 Focal and Multifocal Neuropathy Revenue Growth (2015-2020)
12 Global Diabetic Neurological Disorder Therapeutic Drug Market Size Forecast (2021-2025)
12.1 Global Diabetic Neurological Disorder Therapeutic Drug Market Size Forecast (2021-2025)
12.2 Global Diabetic Neurological Disorder Therapeutic Drug Market Forecast by Regions (2021-2025)
12.3 North America Diabetic Neurological Disorder Therapeutic Drug Revenue Market Forecast (2021-2025)
12.4 Europe Diabetic Neurological Disorder Therapeutic Drug Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Diabetic Neurological Disorder Therapeutic Drug Revenue Market Forecast (2021-2025)
12.6 South America Diabetic Neurological Disorder Therapeutic Drug Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Diabetic Neurological Disorder Therapeutic Drug Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Diabetic Neurological Disorder Therapeutic Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Diabetic Neurological Disorder Therapeutic Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Diabetic Neurological Disorder Therapeutic Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Diabetic Neurological Disorder Therapeutic Drug Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. AstraZeneca Corporate Information, Location and Competitors
Table 7. AstraZeneca Diabetic Neurological Disorder Therapeutic Drug Major Business
Table 8. AstraZeneca Diabetic Neurological Disorder Therapeutic Drug Total Revenue (USD Million) (2017-2018)
Table 9. AstraZeneca SWOT Analysis
Table 10. AstraZeneca Diabetic Neurological Disorder Therapeutic Drug Product and Solutions
Table 11. AstraZeneca Diabetic Neurological Disorder Therapeutic Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. MediciNova Corporate Information, Location and Competitors
Table 13. MediciNova Diabetic Neurological Disorder Therapeutic Drug Major Business
Table 14. MediciNova Diabetic Neurological Disorder Therapeutic Drug Total Revenue (USD Million) (2018-2019)
Table 15. MediciNova SWOT Analysis
Table 16. MediciNova Diabetic Neurological Disorder Therapeutic Drug Product and Solutions
Table 17. MediciNova Diabetic Neurological Disorder Therapeutic Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Mitsubishi Chemical Corporate Information, Location and Competitors
Table 19. Mitsubishi Chemical Diabetic Neurological Disorder Therapeutic Drug Major Business
Table 20. Mitsubishi Chemical Diabetic Neurological Disorder Therapeutic Drug Total Revenue (USD Million) (2017-2018)
Table 21. Mitsubishi Chemical SWOT Analysis
Table 22. Mitsubishi Chemical Diabetic Neurological Disorder Therapeutic Drug Product and Solutions
Table 23. Mitsubishi Chemical Diabetic Neurological Disorder Therapeutic Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Johnson & Johnson Corporate Information, Location and Competitors
Table 25. Johnson & Johnson Diabetic Neurological Disorder Therapeutic Drug Major Business
Table 26. Johnson & Johnson Diabetic Neurological Disorder Therapeutic Drug Total Revenue (USD Million) (2017-2018)
Table 27. Johnson & Johnson SWOT Analysis
Table 28. Johnson & Johnson Diabetic Neurological Disorder Therapeutic Drug Product and Solutions
Table 29. Johnson & Johnson Diabetic Neurological Disorder Therapeutic Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Immune Pharmaceuticals Corporate Information, Location and Competitors
Table 31. Immune Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Major Business
Table 32. Immune Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Total Revenue (USD Million) (2017-2018)
Table 33. Immune Pharmaceuticals SWOT Analysis
Table 34. Immune Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Product and Solutions
Table 35. Immune Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Takeda Corporate Information, Location and Competitors
Table 37. Takeda Diabetic Neurological Disorder Therapeutic Drug Major Business
Table 38. Takeda Diabetic Neurological Disorder Therapeutic Drug Total Revenue (USD Million) (2017-2018)
Table 39. Takeda SWOT Analysis
Table 40. Takeda Diabetic Neurological Disorder Therapeutic Drug Product and Solutions
Table 41. Takeda Diabetic Neurological Disorder Therapeutic Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Dong-A Pharmaceutical Co., Ltd. Corporate Information, Location and Competitors
Table 43. Dong-A Pharmaceutical Co., Ltd. Diabetic Neurological Disorder Therapeutic Drug Major Business
Table 44. Dong-A Pharmaceutical Co., Ltd. Diabetic Neurological Disorder Therapeutic Drug Total Revenue (USD Million) (2017-2018)
Table 45. Dong-A Pharmaceutical Co., Ltd. SWOT Analysis
Table 46. Dong-A Pharmaceutical Co., Ltd. Diabetic Neurological Disorder Therapeutic Drug Product and Solutions
Table 47. Dong-A Pharmaceutical Co., Ltd. Diabetic Neurological Disorder Therapeutic Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Avanir Pharmaceuticals Corporate Information, Location and Competitors
Table 49. Avanir Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Major Business
Table 50. Avanir Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Total Revenue (USD Million) (2017-2018)
Table 51. Avanir Pharmaceuticals SWOT Analysis
Table 52. Avanir Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Product and Solutions
Table 53. Avanir Pharmaceuticals Diabetic Neurological Disorder Therapeutic Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Sangamo BioSciences Corporate Information, Location and Competitors
Table 55. Sangamo BioSciences Diabetic Neurological Disorder Therapeutic Drug Major Business
Table 56. Sangamo BioSciences Diabetic Neurological Disorder Therapeutic Drug Total Revenue (USD Million) (2017-2018)
Table 57. Sangamo BioSciences SWOT Analysis
Table 58. Sangamo BioSciences Diabetic Neurological Disorder Therapeutic Drug Product and Solutions
Table 59. Sangamo BioSciences Diabetic Neurological Disorder Therapeutic Drug Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Global Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) by Players (2015-2020)
Table 61. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Share by Players (2015-2020)
Table 62. Global Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) by Regions (2015-2020)
Table 63. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Regions (2015-2020)
Table 64. North America Diabetic Neurological Disorder Therapeutic Drug Revenue by Countries (2015-2020)
Table 65. North America Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Countries (2015-2020)
Table 66. Europe Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) by Countries (2015-2020)
Table 67. Asia-Pacific Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) by Countries (2015-2020)
Table 68. South America Diabetic Neurological Disorder Therapeutic Drug Revenue by Countries (2015-2020)
Table 69. South America Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Countries (2015-2020)
Table 70. Middle East and Africa Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) by Countries (2015-2020)
Table 71. Middle East and Africa Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Countries (2015-2020)
Table 72. Global Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) by Type (2015-2020)
Table 73. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Share by Type (2015-2020)
Table 74. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Forecast by Type (2021-2025)
Table 75. Global Diabetic Neurological Disorder Therapeutic Drug Revenue by Application (2015-2020)
Table 76. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Share by Application (2015-2020)
Table 77. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Forecast by Application (2021-2025)
Table 78. Global Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Diabetic Neurological Disorder Therapeutic Drug Picture
Figure 2. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Type in 2019
Figure 3. Capsule Picture
Figure 4. Pills Picture
Figure 5. Other Picture
Figure 6. Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Application in 2019
Figure 7. Symmetrical Neuropathy Picture
Figure 8. Focal and Multifocal Neuropathy Picture
Figure 9. Global Diabetic Neurological Disorder Therapeutic Drug Revenue (USD Million) and Growth Rate (2015-2025)
Figure 10. North America Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Europe Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Asia-Pacific Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. South America Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Middle East and Africa Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Share by Players in 2019
Figure 17. Global Top 5 Players Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share in 2019
Figure 18. Global Top 10 Players Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share in 2019
Figure 19. Key Players Market Share Trend
Figure 20. Global Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 21. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Regions (2015-2020)
Figure 22. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Regions in 2018
Figure 23. North America Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 24. Europe Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 25. Asia-Pacific Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 26. South America Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 27. Middle East and Africa Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 28. North America Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Countries (2015-2020)
Figure 29. North America Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Countries in 2019
Figure 30. USA Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 31. Canada Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 32. Mexico Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 33. Europe Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Countries (2015-2020)
Figure 34. Europe Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Countries in 2019
Figure 35. Germany Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 36. UK Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 37. France Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 38. Russia Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 39. Italy Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Countries (2015-2020)
Figure 41. Asia-Pacific Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Countries in 2019
Figure 42. China Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 43. Japan Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 44. Korea Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 45. India Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 46. Southeast Asia Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 47. South America Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Countries (2015-2020)
Figure 48. South America Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Countries in 2019
Figure 49. Brazil Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 50. Argentina Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 51. Middle East and Africa Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Countries (2015-2020)
Figure 52. Middle East and Africa Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share by Countries in 2019
Figure 53. Saudi Arabia Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 54. UAE Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 55. Egypt Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 56. South Africa Diabetic Neurological Disorder Therapeutic Drug Revenue and Growth Rate (2015-2020)
Figure 57. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Share by Type (2015-2020)
Figure 58. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Share by Type in 2019
Figure 59. Global Diabetic Neurological Disorder Therapeutic Drug Market Share Forecast by Type (2021-2025)
Figure 60. Global Capsule Revenue Growth Rate (2015-2020)
Figure 61. Global Pills Revenue Growth Rate (2015-2020)
Figure 62. Global Other Revenue Growth Rate (2015-2020)
Figure 63. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Share by Application (2015-2020)
Figure 64. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Share by Application in 2019
Figure 65. Global Diabetic Neurological Disorder Therapeutic Drug Market Share Forecast by Application (2021-2025)
Figure 66. Global Symmetrical Neuropathy Revenue Growth Rate (2015-2020)
Figure 67. Global Focal and Multifocal Neuropathy Revenue Growth Rate (2015-2020)
Figure 68. Global Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 69. Global Diabetic Neurological Disorder Therapeutic Drug Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 70. Global Diabetic Neurological Disorder Therapeutic Drug Revenue Market Share Forecast by Regions (2021-2025)
Figure 71. North America Diabetic Neurological Disorder Therapeutic Drug Revenue Market Forecast (2021-2025)
Figure 72. Europe Diabetic Neurological Disorder Therapeutic Drug Revenue Market Forecast (2021-2025)
Figure 73. Asia-Pacific Diabetic Neurological Disorder Therapeutic Drug Revenue Market Forecast (2021-2025)
Figure 74. South America Diabetic Neurological Disorder Therapeutic Drug Revenue Market Forecast (2021-2025)
Figure 75. Middle East and Africa Diabetic Neurological Disorder Therapeutic Drug Revenue Market Forecast (2021-2025)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
糖尿病性神経障害治療薬の世界市場（～2026年） A drug used to treat mental illness caused by diabetes Market Analysis and Insights: Global Diabetic Neurological Disorder Therapeutic Drug Market The global Diabetic Neurological Disorder Therapeutic Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CA…- 神経障害治療薬の世界市場（～2026年） Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively su…
- 糖尿病性黄斑浮腫治療薬の世界市場（～2026年） Market Analysis and Insights: Global Diabetic Macular Edema Drug Market The global Diabetic Macular Edema Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Diabetic Macular Edema Drug Scope and Market Size Diabetic …
- 色素沈着障害治療の世界市場（～2026年） Skin pigmentation refers to a skin disorder that causes either lightening of skin or darkening of skin when compared to the existing skin color. Pigmentation therapies can be classified as topical drugs, microdermabrasion, chemical peels, phototherapy, and laser therapy. These therapies are availabl…
- 糖尿病性足潰瘍治療の世界市場（～2026年） Market Analysis and Insights: Global Diabetic Foot Ulcer Therapeutic Market The global Diabetic Foot Ulcer Therapeutic market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Diabetic Foot Ulcer Therapeutic Scope and Market Si…